[1] Chen P, Li Z, Hu Y.Prevalence of osteoporosis in China: a meta-analysis and systematic review[J]. BMC Public Health,2016,16(1):1039.
[2] Xu Y, Wang L, He J, et al.Prevalence and control of dia-betes in Chinese adults[J]. JAMA,2013,310(9):948-959.
[3] Bonds DE, Larson JC, Schwartz AV, et al.Risk of fracture in women with type 2 diabetes: the Women's Health Initiative Observational Study[J]. J Clin Endocrinol Metab,2006,91(9):3404-3410.
[4] Leslie WD, Rubin MR, Schwartz AV, et al.Type 2 diabetes and bone[J]. J Bone Miner Res,2012,27(11):2231-2237.
[5] 中国健康促进基金会骨质疏松防治中国白皮书编委会. 骨质疏松症中国白皮书[J]. 中华健康管理学杂志,2009,3(3):148-154.
[6] Cui L, Chen L, Xia W, et al.Vertebral fracture in postmenopausal Chinese women: a population-based study[J]. Osteoporos Int,2017,28(9):2583-2590.
[7] Tian L, Yang R, Wei L, et al.Prevalence of osteoporosis and related lifestyle and metabolic factors of postmenopausal women and elderly men: A cross-sectional study in Gansu province, Northwestern of China[J]. Medicine (Baltimore),2017,96(43):e8294.
[8] Lin H, Li Q, Hu Y, et al.The prevalence of multiple non-communicable diseases among middle-aged and elderly people: the Shanghai Changfeng Study[J]. Eur J Epidemiol,2017,32(2):159-163.
[9] Nicodemus KK, Folsom AR, Iowa Women's Health Study. Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women[J]. Diabetes Care,2001, 24(7):1192-1197.
[10] Ahmed LA, Joakimsen RM, Berntsen GK, et al.Diabetes mellitus and the risk of non-vertebral fractures: the Tromsø study[J]. Osteoporos Int,2006,17(4):495-500.
[11] Janghorbani M, Van Dam RM, Willett WC, et al.Syste-matic review of type 1 and type 2 diabetes mellitus and risk of fracture[J]. Am J Epidemiol,2007,166(5):495-505.
[12] Zhukouskaya VV, Eller-Vainicher C, Vadzianava VV, et al.Prevalence of morphometric vertebral fractures in patients with type 1 diabetes[J]. Diabetes Care,2013,36(6):1635-1640.
[13] Vestergaard P.Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes--a meta-analysis[J]. Osteoporos Int,2007,18(4):427-444.
[14] Koh WP, Wang R, Ang LW, et al.Diabetes and risk of hip fracture in the Singapore Chinese Health Study[J]. Diabetes Care,2010,33(8):1766-1770.
[15] Janghorbani M, Feskanich D, Willett WC, et al.Prospective study of diabetes and risk of hip fracture: the Nurses' Health Study[J]. Diabetes Care,2006,29(7):1573-1578.
[16] Bortolin RH, Freire Neto FP, Arcaro CA, et al.Anabolic Effect of Insulin Therapy on the Bone: Osteoprotegerin and Osteocalcin Up-Regulation in Streptozotocin-Induced Diabetic Rats[J]. Basic Clin Pharmacol Toxicol,2017,120(3):227-234.
[17] Shimazu J, Wei J, Karsenty G.Smurf1 Inhibits Osteoblast Differentiation, Bone Formation, and Glucose Homeostasis through Serine 148[J]. Cell Rep,2016,15(1):27-35.
[18] Kream BE, Smith MD, Canalis E, et al.Characterization of the effect of insulin on collagen synthesis in fetal rat bone[J]. Endocrinology,1985,116(1):296-302.
[19] Shanbhogue VV, Finkelstein JS, Bouxsein ML, et al.Association Between Insulin Resistance and Bone Structure in Nondiabetic Postmenopausal Women[J]. J Clin Endocrinol Metab,2016,101(8):3114-3122.
[20] Losada-Grande E, Hawley S, Soldevila B, et al.Insulin use and Excess Fracture Risk in Patients with Type 2 Diabetes: A Propensity-Matched cohort analysis[J]. Sci Rep,2017,7(1):3781.
[21] Bartl R, Moser W, Burkhardt R, et al.Diabetic osteomyelopathy: histobioptic data of bone and bone marrow in diabetes mellitus (author's transl)[J]. Klin Wochenschr,1978,56(15):743-754.
[22] Zhang J, Motyl KJ, Irwin R, et al.Loss of Bone and Wnt10b Expression in Male Type 1 Diabetic Mice Is Blocked by the Probiotic Lactobacillus reuteri[J]. Endocrinology,2015,156(9):3169-3182.
[23] Tangvarasittichai S, Pongthaisong S, Tangvarasittichai O.Tumor Necrosis Factor-Α, Interleukin-6, C-Reactive Protein Levels and Insulin Resistance Associated with Type 2 Diabetes in Abdominal Obesity Women[J]. Indian J Clin Biochem,2016,31(1):68-74.
[24] Glantschnig H, Fisher JE, Wesolowski G, et al.M-CSF, TNFalpha and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase[J]. Cell Death Differ,2003,10(10):1165-1177.
[25] Gilbert L, He X, Farmer P, et al.Inhibition of osteoblast differentiation by tumor necrosis factor-alpha[J]. Endocrinology,2000,141(11):3956-3964.
[26] Kim JY, Lee SK, Jo KJ, et al.Exendin-4 increases bone mineral density in type 2 diabetic OLETF rats potentially through the down-regulation of SOST/sclerostin in osteocytes[J]. Life Sci,2013,92(10):533-540.
[27] Monami M, Dicembrini I, Antenore A, et al.Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials[J]. Diabetes Care,2011,34(11):2474-2476.
[28] Mamza J, Marlin C, Wang C, et al.DPP-4 inhibitor the-rapy and bone fractures in people with Type 2 diabetes-A systematic review and meta-analysis[J]. Diabetes Res Clin Pract,2016,116:288-298.
[29] Driessen JH, van Onzenoort HA, Henry RM, et al. Use of dipeptidyl peptidase-4 inhibitors for type 2 diabetes mellitus and risk of fracture[J]. Bone,2014,68:124-130.
[30] Yang Y, Zhao C, Liang J, et al.Effect of Dipeptidyl Peptidase-4 Inhibitors on Bone Metabolism and the Possible Underlying Mechanisms[J]. Front Pharmacol,2017,8:487.
[31] Mabilleau G, Mieczkowska A, Chappard D.Use of glucagon-like peptide-1 receptor agonists and bone fractures: a meta-analysis of randomized clinical trials[J]. J Diabetes,2014,6(3):260-266.
[32] Styner M, Pagnotti GM, Galior K, et al.Exercise Regulation of Marrow Fat in the Setting of PPARγ Agonist Treatment in Female C57BL/6 Mice[J]. Endocrinology,2015,156(8):2753-2761.
[33] Yu OH, Richards B, Berger C, et al.The association between sclerostin and incident type 2 diabetes risk: a cohort study[J]. Clin Endocrinol (Oxf),2017,86(4):520-525.
[34] Devlin MJ, Rosen CJ.The bone-fat interface: basic and clinical implications of marrow adiposity[J]. Lancet Diabetes Endocrinol,2015,3(2):141-147.
[35] Baum T, Yap SP, Karampinos DC, et al.Does vertebral bone marrow fat content correlate with abdominal adipose tissue, lumbar spine bone mineral density, and blood biomarkers in women with type 2 diabetes mellitus?[J]. J Magn Reson Imaging,2012,35(1):117-124.
[36] Marycz K, Tomaszewski KA, Kornicka K, et al.Metformin Decreases Reactive Oxygen Species, Enhances Osteogenic Properties of Adipose-Derived Multipotent Mesenchymal Stem Cells In Vitro, and Increases Bone Density In Vivo[J]. Oxid Med Cell Longev,2016,2016:9785890.
[37] Montagnani A, Gonnelli S, Alessandri M, et al.Osteoporosis and risk of fracture in patients with diabetes: an update[J]. Aging Clin Exp Res,2011,23(2):84-90.
[38] Melton LJ 3rd, Leibson CL, Achenbach SJ, et al. Fracture risk in type 2 diabetes: update of a population-based study[J]. J Bone Miner Res,2008,23(8):1334-1342.
[39] Majumdar SR, Josse RG, Lin M, et al.Does Sitagliptin Affect the Rate of Osteoporotic Fractures in Type 2 Diabetes? Population-Based Cohort Study[J]. J Clin Endocrinol Metab,2016,101(5):1963-1669.
[40] Kanazawa I, Yamaguchi T, Yamamoto M, et al.Relationship between treatments with insulin and oral hypoglycemic agents versus the presence of vertebral fractures in type 2 diabetes mellitus[J]. J Bone Miner Metab,2010, 28(5):554-560.
[41] Watts NB, Bilezikian JP, Usiskin K, et al.Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus[J]. J Clin Endocrinol Metab,2016,101(1):157-166.
[42] Ptaszynska A, Johnsson KM, Parikh SJ, et al.Safety profile of dapagliflozin for type 2 diabetes: pooled analysis of clinical studies for overall safety and rare events[J]. Drug Saf,2014,37(10):815-829.
[43] Thrailkill KM, Nyman JS, Bunn RC, et al.The impact of SGLT2 inhibitors, compared with insulin, on diabetic bone disease in a mouse model of type 1 diabetes[J]. Bone,2017,94:141-151.
[44] Gilbert MP, Pratley RE.The impact of diabetes and diabetes medications on bone health[J]. Endocr Rev,2015, 36(2):194-213.
[45] Coyoy A, Guerra-Araiza C, Camacho-Arroyo I.Metabolism Regulation by Estrogens and Their Receptors in the Central Nervous System Before and After Menopause[J]. Horm Metab Res,2016,48(8):489-496.
[46] Loh NY, Neville MJ, Marinou K, et al.LRP5 regulates human body fat distribution by modulating adipose progenitor biology in a dose- and depot-specific fashion[J]. Cell Metab,2015,21(2):262-272.
[47] Keenan HA, Maddaloni E.Bone Microarchitecture in Type 1 Diabetes: It Is Complicated[J]. Curr Osteoporos Rep,2016,14(6):351-358.
[48] Hamann C, Kirschner S, Günther KP, et al.Bone, sweet bone--osteoporotic fractures in diabetes mellitus[J]. Nat Rev Endocrinol,2012,8(5):297-305.
[49] Botushanov NP, Orbetzova MM.Bone mineral density and fracture risk in patients with type 1 and type 2 diabetes mellitus[J]. Folia Med (Plovdiv),2009,51(4):12-17.
[50] Verroken C, Pieters W, Beddeleem L, et al.Cortical Bone Size Deficit in Adult Patients With Type 1 Diabetes Mellitus[J]. J Clin Endocrinol Metab,2017,102(8):2887-2895.
[51] Boutroy S, Bouxsein ML, Munoz F, et al.In vivo assessment of trabecular bone microarchitecture by high-resolution peripheral quantitative computed tomography[J]. J Clin Endocrinol Metab,2005,90(12):6508-6515.
[52] Shanbhogue VV, Hansen S, Frost M, et al.Bone Geometry, Volumetric Density, Microarchitecture, and Estimated Bone Strength Assessed by HR-pQCT in Adult Patients With Type 1 Diabetes Mellitus[J]. J Bone Miner Res,2015,30(12):2188-2199.
[53] Burghardt AJ, Issever AS, Schwartz AV, et al.High-resolution peripheral quantitative computed tomographic imaging of cortical and trabecular bone microarchitecture in patients with type 2 diabetes mellitus[J]. J Clin Endocrinol Metab,2010,95(11):5045-5055.
[54] Samelson EJ, Demissie S, Cupples LA, et al.Diabetes and Deficits in Cortical Bone Density, Microarchitecture, and Bone Size: Framingham HR-pQCT Study[J]. J Bone Miner Res,2018,33(1):54-62.
[55] Nilsson AG, Sundh D, Johansson L, et al.Type 2 Diabetes Mellitus Is Associated With Better Bone Microarchitecture But Lower Bone Material Strength and Poorer Physical Function in Elderly Women: A Population-Based Study[J]. J Bone Miner Res,2017,32(5):1062-1071.
[56] 中华医学会骨质疏松和骨矿盐疾病分会. 原发性骨质疏松症诊疗指南(2017)[J]. 中华骨质疏松和骨矿盐疾病杂志,2017,10(5):413-441.
